Research Paper Volume 14, Issue 17 pp 7170—7185
A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma
Figure 6. Clinical application of CR-related gene signature for PRAD patients. (A) Multivariate Cox regression was used to investigate the ability of age, clinical T stage, clinical N stage, Gleason score, prostate specific antigen (PSA) and the CR-related gene signature (risk score) to predict RFS. Risk score remained to be a valid predictor (P<0.05). (B) A nomogram combing risk score and clinical T stage was constructed to predict 1-, 3- and 5-year RFS for individual PRAD patient. (C) ROC analysis for nomogram showed an impressive predictive performance, with AUC of 0.944. (D) Calibration curve showed agreement between actual and predicted RFS, indicating an ideal predictive capability.